Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study
- Cassinotti, Andrea
- Mezzina, Nicolò
- De Silvestri, Annalisa
- Di Paolo, Dhanai
- Lenti, Marco Vincenzo
- Bezzio, Cristina
- Stradella, Davide
- Mauri, Martina
- Zadro, Valentina
- Ricci, Chiara
- Casini, Valentina
- Radice, Elisa
- Massari, Alessandro
- Maconi, Giovanni
- Saibeni, Simone
- Caprioli, Flavio
- Tari, Roberto
- Fichera, Maria
- Cortelezzi, Claudio Camillo
- Parravicini, Marco
- Tinelli, Carmine
- Testoni, Pier Alberto
- Pace, Fabio
- Segato, Sergio
- Invernizzi, Pietro
- Occhipinti, Pietro
- Manes, Gianpiero
- Di Sabatino, Antonio
- Pastorelli, Luca
- Vecchi, Maurizio
- Ardizzone, Sandro
Publication date
January 2022
DOIAbstract
Comparative trials among biological drugs for the treatment of ulcerative colitis (UC) provided conflicting results. After patent expire of infliximab originator, adalimumab, infliximab biosimilar, golimumab and vedolizumab have been approved in Italy.We compared the efficacy of these four biologics in UC according to the concept of continuous clinical remission (CCR)
Add to ORKG